Compositions comprising bacterial strains
The invention provides compositions comprising bacterial strains for treating and preventing cancer.
1. A method of increasing a level of an IL-6 or TNF-α cytokine in a subject in need thereof, comprising administering to said subject a pharmaceutical composition that comprises: (a) a bacteria strain of the species Enterococcus gallinarum that comprises a 16s rRNA gene sequence with at least 99.5% sequence identity to the polynucleotide of SEQ ID NO: 2, wherein said sequence identity is determined by the Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12 and a gap extension penalty of 2, and a BLOSUM matrix of 62, and (b) a prebiotic compound, wherein said administering is sufficient to increase said level of said IL-6 or TNF-α cytokine at least 100-fold relative to prior to said administering.
2. The method of claim 1 , wherein said administering is sufficient to increase said level of said IL-6 cytokine.
3. The method of claim 2 , wherein said administering is sufficient to increase said level of said IL-6 cytokine at least 600-fold, relative to prior to said administering.
4. The method of claim 1 , wherein said administering is sufficient to increase said level of said TNF-α cytokine.
5. The method of claim 4 , wherein said administering is sufficient to increase said level of said IL-6 cytokine at least 400-fold, relative to prior to said administering.
6. The method of claim 1 , wherein said pharmaceutical composition further comprises a lipopolysaccharide.
7. The method of claim 6 , wherein said administering is sufficient to increase a level of an IL-1β cytokine at least 1000-fold, relative to prior to said administering.
8. The method of claim 1 , wherein said amount of said bacteria strain comprises from about 1×10 3 to about 1×10 11 CFU/g of said bacteria strain with respect to a total weight of said pharmaceutical composition.
9. The method of claim 1 , wherein said pharmaceutical composition is formulated for oral delivery.
10. The method of claim 1 , wherein said pharmaceutical composition is formulated for delivery to an intestine of said subject.
11. The method of claim 1 , wherein said subject is human.
12. The method of claim 1 , wherein said prebiotic compound is selected from the group consisting of: a fructo-oligosaccharide, a short-chain fructo-oligosaccharide, inulin, an isomalt-oligosaccharide, a transgalacto-oligosaccharide, a pectin, a xylo-oligosaccharide, a chitosan-oligosaccharide, a beta-glucan, an arable gum modified starch, a polydextrose, a D-tagatose, an acacia fiber, carob, an oat, and a citrus fiber.